Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis.
Saved in:
| Title: | Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis. |
|---|---|
| Authors: | Rudofsky G; Praxis für Endokrinologie, Diabetes und Adipositas, Olten, Solothurn, Switzerland. Gottfried.rudofsky@hin.ch., Menzen M; Gemeinschaftskrankenhaus, Bonn, Germany., Potier L; Université Paris Cité, AP-HP, Bichat Hospital, INSERM U1151, CNRS UMR8253, Institut Necker Enfants Malades, Paris, France., Catarig AM; Novo Nordisk A/S, Søborg, Denmark., Clark A; Novo Nordisk A/S, Søborg, Denmark., Priyadarshini P; Novo Nordisk GBS, Bengaluru, India., Abreu C; Endocrinology and Nutrition Unit, Segovia General Hospital, Segovia, Spain. |
| Source: | Advances in therapy [Adv Ther] 2025 Feb; Vol. 42 (2), pp. 788-800. Date of Electronic Publication: 2024 Dec 05. |
| Publication Type: | Journal Article; Observational Study |
| Journal Info: | Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-8652 (Electronic) Linking ISSN: 0741238X NLM ISO Abbreviation: Adv Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1865-8652 |
|---|---|
| DOI: | 10.1007/s12325-024-03000-x |
